Hangzhou Biotest Biotech Co Ltd (688767) — Capital Reinvestment Ratio
Hangzhou Biotest Biotech Co Ltd (688767) has a Capital Reinvestment Ratio of 1.66x as of September 2025, meaning it reinvests 2% of its operating cash flow (CN¥28.39 Million) in capital expenditures (CN¥47.02 Million). See Hangzhou Biotest Biotech Co Ltd (688767) balance sheet quality index to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Hangzhou Biotest Biotech Co Ltd Capital Reinvestment Ratio (2017–2025)
This chart tracks Hangzhou Biotest Biotech Co Ltd's Capital Reinvestment Ratio across 9 annual periods. Check 688767 cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Hangzhou Biotest Biotech Co Ltd (2017–2025)
Year-by-year Capital Reinvestment Ratio for Hangzhou Biotest Biotech Co Ltd from 2017 to 2025. For live market cap and broader valuation context, see market cap of Hangzhou Biotest Biotech Co Ltd.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 1.22x | CN¥106.47 Million | CN¥129.87 Million | ▼ -35.9% |
| 2024 | 1.90x | CN¥128.83 Million | CN¥245.05 Million | ▲ +342.9% |
| 2023 | 0.43x | CN¥131.38 Million | CN¥56.42 Million | ▲ +68.8% |
| 2022 | 0.25x | CN¥703.21 Million | CN¥178.92 Million | ▲ +15.4% |
| 2021 | 0.22x | CN¥908.12 Million | CN¥200.20 Million | ▲ +70.5% |
| 2020 | 0.13x | CN¥446.07 Million | CN¥57.68 Million | ▼ -91.6% |
| 2019 | 1.54x | CN¥25.67 Million | CN¥39.47 Million | ▲ +157.0% |
| 2018 | 0.60x | CN¥21.17 Million | CN¥12.67 Million | ▼ -83.9% |
| 2017 | 3.73x | CN¥7.07 Million | CN¥26.37 Million | — |